PURPOSE: To determine the prevalence rates and associated characteristics of @entity1 who have ocular surface, ocular adnexal, and lacrimal complications associated with the systemic use of the @entity5 chemotherapeutic agent @entity1487 ( @entity1487 ). METHODS: An exposure-based cohort study was designed. Adult @entity1 who had completed at least 3 months of systemic @entity1487 therapy within the past 5 years were eligible for enrollment. Study subjects had a detailed medical history taken with emphasis on preexisting conditions known to be associated with the development of ocular surface, ocular adnexal, and lacrimal complications. An ocular examination was then performed. A complete nasolacrimal system evaluation was performed if symptoms or findings were identified. The prevalence was then determined for each ocular symptom and each ocular finding identified that was not present pretreatment. An exploratory analysis was then performed to identify @entity1 characteristics that might influence the likelihood of developing any of the above complications. RESULTS: Fifty-two @entity1 were enrolled in the study. The prevalence rates of the following ocular abnormalities were calculated: ocular irritation, 5.8%; @entity14985 , 3.8%; @entity2024 , 3.8%; @entity1036 , 3.8%; @entity1909 , 5.8%; cicatricial ectropion, 1.9%; tearing, 26.9%; punctal-canalicular @entity850 , 5.8%; and blurred vision, 11.5%. Blacks had tearing at a significantly higher rate when compared with whites (P = 0.022, 2-sided Fisher exact test). Three @entity1 had permanent complications that will require surgery for correction. Of the 7 @entity1 who had a single abnormality, 6 had tearing and one had @entity1909 . All of the 8 @entity1 who had multiple findings had tearing as one of their abnormalities. CONCLUSIONS: Ninety-three percent of the @entity1 who had an @entity735 had tearing as one of the complications. @entity1 who are receiving systemic @entity1487 and begin to tear should have an ocular examination, looking for ocular surface, ocular adnexal, and lacrimal complications.

Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity1036 :: ('MESH:D007634', 'Disease') :: ['keratitis'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer'] @entity14985 :: ('MESH:D001762', 'Disease') :: ['blepharitis'] @entity735 :: ('MESH:D005124', 'Disease') :: ['ocular abnormality'] @entity2024 :: ('MESH:D003231', 'Disease') :: ['conjunctivitis'] @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis'] @entity1909 :: ('MESH:D003872', 'Disease') :: ['eyelid dermatitis'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-Fluorouracil', '5-FU']
@entity1487 :: (MESH:D005472,Chemical) :: ['5-fluorouracil']
